Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2011. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on share capital movements.
- Shares Purchased: 1,200,000 Ordinary shares of 25 pence each.
- Purchase Date: June 7, 2011.
- Price Range: Highest price paid was 1,312.5 pence per share; lowest price paid was 1,299.5 pence per share.
- Treasury Shares: 499,174,284 shares held in Treasury (8.83% of total issued share capital; 9.68% of total voting rights).
- Shares in Issue: 5,155,464,934 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of issued share capital through the cancellation of 1,200,000 repurchased shares. Consequently, the total number of shares in issue decreased to 5,155,464,934. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the updated total issued share capital of 5,155,464,934 shares for calculating ownership thresholds.
- Confirm the Treasury share count of 499,174,284 and its impact on voting rights (9.68%).
- Review the specific price range (1,299.5p to 1,312.5p) paid for the repurchased shares.
- Note that this filing does not contain financial performance results; refer to the most recent Form 20-F or interim reports for revenue and profit data.